eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search

Open access

without publication fees
3/2024
vol. 26
 
Share:
Send email
Share:
Review paper

Polish expert group recommendations for RSV vaccination in adults

Aneta Nitsch-Osuch
1
,
Adam Antczak
2
,
Adam Barczyk
3
,
Leszek Czupryniak
4
,
Marcin Grabowski
5
,
Maciej Kupczyk
6
,
Justyna Ledwoch
7
,
Agnieszka Mastalerz-Migas
8
,
Michał Sutkowski
9
,
Filip Szymański
10
,
Jacek Wysocki
11

  1. Department of Social Medicine and Public Health, Medical University of Warsaw, Warsaw, Poland; Polish Society of Family Medicine
  2. Department of General and Oncological Pulmonology, Medical University of Lodz, Lodz, Poland
  3. Chair and Department of Pneumology, Medical University of Silesia in Katowice, Katowice, Poland; Polish Society of Lung Diseases
  4. Department of Diabetology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland; Polish Diabetes Association
  5. Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
  6. Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Lodz, Poland; Polish Society of Allergology
  7. Polish Society of Family Medicine
  8. Department of Family Medicine, Wroclaw Medical University, Wroclaw, Poland; Polish Society of Family Medicine
  9. Łazarski University, Warsaw; Warsaw, Poland; College of Family Physicians in Poland
  10. Chair of Civilization Diseases, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszyński University in Warsaw, Warsaw, Poland; Polish Cardiac Society
  11. Department of Preventive Medicine, Poznan University of Medical Sciences, Poznan, Poland; Polish Vaccinology Society
Family Medicine & Primary Care Review 2024; 26(3): 402–407
DOI: https://doi.org/10.5114/fmpcr.2024.142015
Online publish date: 2024/09/30
Article file
- 16 FM&PCR 3 24 - R - Nitsch-Osuch - 1580 - Polish ehpert group.pdf  [0.44 MB]
Get citation
 
PlumX metrics:
 
1. Rima B, Collins P, Easton A, et al. ICTV virus taxonomy profile: Pneumoviridae. J Gen Virol 2017; 98: 2912–2913.
2. Gilca R, De Serres G, Tremblay M, et al. Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons. J Infect Dis 2006; 193: 54–58.
3. Centers for Disease Control and Prevention. RSV Transmission [cited 29.08.2023]. Available from URL: https://www.cdc.gov/rsv/about/transmission.html.
4. Gralton J, Tovey ER, McLaws ML, et al. Respiratory virus RNA is detectable in airborne and droplet particles. J Med Virol 2013; 85: 2151–2159.
5. Reis J, Shaman J. Retrospective parameter estimation and forecast of respiratory syncytial virus in the United States. PLoS Comput Biol 2016; 12: e1005133.
6. Otomaru H, Sornillo JBT, Kamigaki T, et al. Risk of transmission and viral shedding from the time of infection for respiratory syncytial virus in households. Am J Epidemiol 2021; 190: 2536–2543.
7. King JC Jr, Burke AR, Clemens JD, et al. Respiratory syncytial virus illnesses in human immunodeficiency virus- and noninfected children. Pediatr Infect Dis J 1993; 12: 733–739.
8. Kaler J, Hussain A, Patel K, et al. Respiratory syncytial virus: a comprehensive review of transmission, pathophysiology, and manifestation. Cureus 2023; 15: e36342.
9. Openshaw PJM, Chiu C, Culley FJ, et al. Protective and harmful immunity to RSV infection. Annu Rev Immunol 2017; 35: 501–532.
10. Walsh EE, Peterson DR, Falsey AR. Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis 2004; 189: 233–238.
11. Jozwik A, Habibi MS, Paras A, et al. RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection. Nat Commun 2015; 6: 10224. Errata: Nat Commun 2016; 7: 11011.
12. Bree GJ, de, Heidema J, Leeuwen EM, van, et al. Respiratory syncytial virus-specific CD8+ memory T cell responses in elderly persons. J Infect Dis 2005; 191: 1710–1718.
13. Rose EB, Wheatley A, Langley G, et al. Respiratory syncytial virus seasonality – United States, 2014–2017. MMWR Morb Mortal Wkly Rep 2018; 67: 71–76.
14. Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, et al. Respiratory syncytial virus seasonality: a global overview. J Infect Dis 2018; 217: 1356–1364.
15. Hamid S, Winn A, Parikh R, et al. Seasonality of respiratory syncytial virus – United States, 2017–2023. MMWR Morb Mortal Wkly Rep 2023; 72: 355–361.
16. Zheng Z, Pitzer VE, Shapiro ED, et al. Estimation of the timing and intensity of reemergence of respiratory syncytial virus following the COVID-19 pandemic in the US. JAMA Netw Open 2021; 4: e2141779.
17. Hall CB, Walsh EE, Long CE, et al. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991; 163: 693–698.
18. Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med 2015; 372: 835–845.
19. Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 2022; 399: 2047–2064.
20. Byington CL, Wilkes J, Korgenski K, et al. Respiratory syncytial virus-associated mortality in hospitalized infants and young children. Pediatrics 2015; 135: e24–e31.
21. O’Shea MK, Ryan MA, Hawksworth AW, et al. Symptomatic respiratory syncytial virus infection in previously healthy young adults living in a crowded military environment. Clin Infect Dis 2005; 41: 311–317.
22. Belongia EA, King JP, Kieke BA, et al. Clinical features, severity, and incidence of RSV illness during 12 consecutive seasons in a community cohort of adults ≥ 60 years old. Open Forum Infect Dis 2018; 5: ofy316.
23. Hall CB, Long CE, Schnabel KC. Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis 2001; 33: 792–796.
24. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev 2000; 13: 371–384.
25. Maggi S, Veronese N, Burgio M, et al. Rate of hospitalizations and mortality of respiratory syncytial virus infection compared to influenza in older people: a systematic review and meta-analysis. Vaccines (Basel) 2022; 10: 2092.
26. Lee N, Lui GC, Wong KT, et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis 2013; 57: 1069–1077.
27. Ackerson B, Tseng H, Sy L, et al. Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults. Clin Infect Dis 2019; 69: 197–203.
28. Falsey AR, Walsh EE, House S, et al. Risk Factors and medical resource utilization of respiratory syncytial virus, human metapneumovirus, and influenza-related hospitalizations in adults – a global study during the 2017–2019 epidemic seasons (Hospitalized Acute Respiratory Tract Infection [HARTI] study). Open Forum Infect Dis 2021; 8: ofab491.
29. Savic M, Penders Y, Shi T, et al. Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis. Influenza Other Respir Viruses 2023; 17: e13031.
30. Rozporządzenie Ministra Zdrowia z dnia 23 lutego 2023 r. w sprawie zakażeń wirusem syncytialnym układu oddechowego (RSV) (Dz.U. 2023 poz. 354) (in Polish).
31. Rozporządzenie Ministra Zdrowia z dnia 5 stycznia 2023 r. Zmieniające rozporządzenie w sprawie świadczeń gwarantowanych z zakresu podstawowej opieki zdrowotnej (Dz.U. 2023 poz. 38) (in Polish).
32. Zakład Epidemiologii Chorób Zakaźnych i Nadzoru NIZP PZH-PIB. Zachorowania na wybrane choroby zakaźne w Polsce od 1 stycznia do 15 sierpnia 2023 r. oraz w porównywalnym okresie 2022 r. [cited 28.08.2023]. Available from URL: http://wwwold.pzh.gov.pl/oldpage/epimeld/2023/INF_23_08A.pdf (in Polish).
33. Osei-Yeboah R, Spreeuwenberg P, Del Riccio M, et al. Estimation of the number of RSV-associated hospitalisations in adults in the European Union. J Infect Dis 2023; 29: jiad189.
34. Anderson NW, Binnicker MJ, Harris DM, et al. Morbidity and mortality among patients with respiratory syncytial virus infection: a 2-year retrospective review. Diagn Microbiol Infect Dis 2016; 85: 367–371.
35. Branche AR, Saiman L, Walsh EE, et al. Incidence of respiratory syncytial virus infection among hospitalized adults, 2017–2020. Clin Infect Dis 2022; 74: 1004–1011.
36. Begley KM, Monto AS, Lamerato LE, et al. Prevalence and clinical outcomes of respiratory syncytial virus vs influenza in adults hospitalized with acute respiratory illness from a prospective multicenter study. Clin Infect Dis 2023; 76: 1980–1988.
37. Wyffels V, Kariburyo F, Gavart S, et al. A real-world analysis of patient characteristics and predictors of hospitalization among US Medicare beneficiaries with respiratory syncytial virus infection. Adv Ther 2020; 37: 1203–1217.
38. Tseng HF, Sy LS, Ackerson B, et al. Severe Morbidity and short- and mid- to long-term mortality in older adults hospitalized with respiratory syncytial virus infection. J Infect Dis 2020; 222: 1298–1310.
39. Volling C, Hassan K, Mazzulli T, et al. Respiratory syncytial virus infection-associated hospitalization in adults: a retrospective cohort study. BMC Infect Dis 2014; 14: 665.
40. Ackerson B, Tseng HF, Sy LS, et al. Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults. Clin Infect Dis 2019; 69: 197–203.
41. Ivey KS, Edwards KM, Talbot HK. Respiratory syncytial virus and associations with cardiovascular disease in adults. J Am Coll Cardiol 2018; 71: 1574–1583.
42. Kujawski SA, Whitaker M, Ritchey MD, et al. Rates of respiratory syncytial virus (RSV)-associated hospitalization among adults with congestive heart failure-United States, 2015–2017. PLoS One 2022; 17: e0264890.
43. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1618–1623.
44. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173: 1114–1121.
45. Linden D, Guo-Parke H, Coyle PV, et al. Respiratory viral infection: a potential “missing link” in the pathogenesis of COPD. Eur Respir Rev 2019; 28: 180063.
46. Zheng XY, Xu YJ, Guan WJ, et al. Regional, age and respiratory-secretion-specific prevalence of respiratory viruses associated with asthma exacerbation: a literature review. Arch Virol 2018; 163: 845–853.
47. Prasad N, Walker TA, Waite B, et al. Respiratory syncytial virus-associated hospitalizations among adults with chronic medical conditions. Clin Infect Dis 2021; 73: e158–e163.
48. Allen KE, Chommanard C, Haynes AK, et al. Respiratory syncytial virus testing capabilities and practices among National Respiratory and Enteric Virus Surveillance System laboratories, United States, 2016. J Clin Virol 2018; 107: 48–51.
49. FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine. US Food & Drug Administration (FDA) approved product information [cited 17.09.2023]. Available from URL: https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine.
50. European Medicines Agency. Arexvy (szczepionka przeciw syncytialnemu wirusowi oddechowemu (RSV) (rekombinowana, z adiuwantem). Przegląd wiedzy na temat szczepionki Arexvy i uzasadnienie udzielenia pozwolenia na dopuszczenie do obrotu w UE [cited 17.09.2023]. Available from URL: https://www.ema.europa.eu/en/documents/overview/arexvy-epar-medicine-overview_pl.pdf (in Polish).
51. Graham BS, Modjarrad K, McLellan JS. Novel antigens for RSV vaccines. Curr Opin Immunol 2015; 35: 30–38.
52. Leroux-Roels I, Davis MG, Steenackers K, et al. Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: phase 1/2 randomized clinical trial. J Infect Dis 2023; 227: 761–772.
53. US Food and Drug Administration. May 31, 2023 Approval Letter – ABRYSVO [cited 17.09.2023]. Available from URL: https://www.fda.gov/media/168890/.
54. European Medicines Agency. Abrysvo (szczepionka przeciw syncytialnemu wirusowi oddechowemu, biwalentna, rekombinowana). Przegląd wiedzy na temat szczepionki Abrysvo i uzasadnienie udzielenia pozwolenia na dopuszczenie do obrotu w UE [cited 17.09.2023]. Available from URL: https://www.ema.europa.eu/en/documents/overview/abrysvo-epar-medicine-overview_pl.pdf (in Polish).
55. Walsh EE, Pérez Marc G, Zareba AM, et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med 2023; 388: 1465–1477.
56. Arexvy: Charakterystyka produktu leczniczego [cited 17.09.2023]. Available from URL: https://www.ema.europa.eu/en/documents/product-information/arexvy-epar-product-information_pl.pdf (in Polish).
57. Abrysvo: Charakterystyka produktu leczniczego [cited 17.09.2023]. Available from URL: https://www.ema.europa.eu/en/documents/product-information/abrysvo-epar-product-information_en.pdf (in Polish).
58. Melgar M, Britton A, Roper LE, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the advisory committee on immunization practices – United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72: 793–801.
59. Komunikat Głównego Inspektora Sanitarnego z dnia 29 września 2023 r. w sprawie Programu Szczepień Ochronnych na rok 2023 (Dz. Urz. Min. Zdr. 2023.87) (in Polish).
60. Papi A, Ison MG, Langley JM, et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med 2023; 388: 595–608.
61. Falsey AR, Walsh EE, Scott DA, et al. Phase 1/2 randomized study of the immunogenicity, safety, and tolerability of a respiratory syncytial virus prefusion F vaccine in adults with concomitant inactivated influenza vaccine. J Infect Dis 2022; 225: 2056–2066.
62. Chandler R, Montenegro N, Llorach C, et al. 2139. Immunogenicity, reactogenicity and safety of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine co-administered with the seasonal quadrivalent influenza vaccine in older adults. Open Forum Infect Dis 2022; 9(Suppl. 2): ofac492.1759.
Copyright: © 2024 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.